miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease
Márcia Cristina Teixeira dos Santos(UCB Pharma (Belgium)), André Nogueira da Costa(UCB Pharma (Belgium)), Rosie Bell(University of Cambridge), D. Scheller, Caroline Berteau(University of Leeds), Luis Tosar Perez(UCB Pharma (Belgium)), Daniela Berg(Christian-Albrechts-Universität zu Kiel), Walter Maetzler(Christian-Albrechts-Universität zu Kiel), Pedro A. F. Galante(Hospital Sírio-Libanês), Claudia Schulte(School of the Art Institute of Chicago), Bruna Renata S. Correia(Hospital Sírio-Libanês), Miguel Arturo Barreto-Sanz, Catherine Widnall(University of Leeds)
Cited by 130
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846